PA
SGI

PharVision Advisers’s Somnigroup International SGI Stock Holding History

PharVision Advisers’s Portfolio SGI Stock Details SGI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,004
Closed -$268K – 692
2025
Q4 		$268K Buy
+3,004
New +$262K 0.14% 342

Other funds holding SGI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LP
Linonia Partnership New York $5.38B AUM 20.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

PharVision Advisers's SGI Position: Q1 2026 in Review

PharVision Advisers sold out of Somnigroup International (SGI) in Q1 2026, closing a stake of 3,004 shares — an estimated $268K sold.

PharVision Advisers first reported a position in SGI in Q4 2025 and held it in 1 quarter. The position peaked at $268K in Q4 2025. 523 funds tracked by Wall St. Rank hold SGI as of Q1 2026.

  • PharVision Advisers reported no remaining Somnigroup International position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 3,004 Somnigroup International shares in Q1 2026, an estimated $268K.
  • PharVision Advisers first reported a position in Somnigroup International in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Somnigroup International position peaked at $268K in Q4 2025.
  • 523 funds tracked by Wall St. Rank held Somnigroup International as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.